Dupixent 300 MG/2 ML pen 2ML
Ended Awarded Last action
- Contract number
- SPE2DR26F9EAQ
- Awardee
-
Amerisourcebergen Drug Corp UEI KABZK8W6PQT3 Part of Cencora, Inc.
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $22,956
Award facts
- Contract value 100% obligated
- $22,955.98 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Conshohocken, PA 19428, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a $22,955.98 firm fixed-price delivery order to AmerSourceBergen Drug Corp on January 30, 2026, for the supply of Dupixent 300 mg/2 ml pen injectors, with an ultimate completion date of February 2, 2026. The contract represents a non-set-aside, competitively awarded procurement executed through the place of performance in Conshohocken, Pennsylvania. This delivery order is issued under AmerSourceBergen's parent company Cencora, Inc.'s broader Indefinite Delivery Contract with DLA Troop Support Medical, valued at up to $999,999,999.00 through December 31, 2031, which serves as the primary vehicle for delivering comprehensive pharmaceutical products and medical supplies to support military healthcare programs globally.
Dupixent (dupilumab) is a specialty biologic medication indicated for multiple conditions including moderate-to-severe atopic dermatitis, eosinophilic esophagitis, and asthma, making it a critical component of the military healthcare supply chain. AmerSourceBergen Drug Corp's role as a major pharmaceutical distributor enables it to fulfill federal medical procurement requirements across multiple therapeutic domains, including specialty medications, brand-name drugs, and medical devices. The non-set-aside status of this award reflects the contractor's demonstrated capability to compete successfully in the open federal marketplace for essential pharmaceutical commodities required by military treatment facilities and other defense health programs.
Quick answers
Who was awarded contract SPE2DR26F9EAQ?
SPE2DR26F9EAQ was awarded to Amerisourcebergen Drug Corp by Defense Logistics Agency (Department of Defense) on January 30, 2026.
How much is contract SPE2DR26F9EAQ worth?
The government has obligated $22,956 on SPE2DR26F9EAQ.
Is contract SPE2DR26F9EAQ an order under another contract?
Yes. SPE2DR26F9EAQ is a delivery order under SPE2DR25D1017, an indefinite delivery contract.
Was contract SPE2DR26F9EAQ competed?
The extent of competition for SPE2DR26F9EAQ was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award